血清HBsAg和HBeAg水平变化与慢性乙型肝炎患者抗病毒疗效预测  

Serum HBsAg and HBeAg levels in the prediction of antiviral efficacy in patients with chronic hepatitis B

作　　者：林沪[1] 李元元[1] 王福生[1] 

机构地区：[1]解放军第302医院肝病生物治疗研究中心,北京市100039

出　　处：《实用肝脏病杂志》2014年第1期98-101,共4页Journal of Practical Hepatology

摘　　要：血清HBsAg或HBeAg定量水平的变化在慢性乙型肝炎(CHB)患者抗病毒治疗的应答中有重要预测价值,可以用于指导和调整治疗方案。本文综述了CHB患者血清HBsAg和HBeAg水平变化与HBV复制指标如血清HBV DNA和肝内HBV cccDNA间的关系,以阐明CHB患者血清HBsAg或HBeAg水平在判定抗病毒疗效方面的新认识。Quantification of serum HBsAg and HBeAg in patients with CHB is useful in the prediction of response to an-tiviral treatment, and they can be used to guide the treatment strategy. Here we reviewed the changes in serum HBsAg and HBeAg levels in patients with CHB and their relations to HBV replication, which include serum HBV DNA, and intrahepatic HBV cccDNA. This review will help to understand the clinical value of serum HBsAg and HBeAg levels in the prediction of an-tiviral efficacy in patients with CHB.

关 键 词：慢性乙型肝炎 乙型肝炎病毒 抗病毒治疗 

分 类 号：R512.62[医药卫生—内科学]